Migraine is characterized by recurrent throbbing headache, which only affects one side of the head. It may be accompanied by vomiting, nausea, and even vision impairment. Increased prevalence of migraine, a sharp increase in the female population, and increased patient awareness of the treatment and prevention of migraine are driving the growth of the worldwide migraine drug market.

However, the side effects of migraine medications are expected to limit the growth of the market. Conversely, new treatments for the treatment of migraine new drugs and growth opportunities in emerging countries are expected to present opportunities for market growth during the forecast period.

Download Sample @ https://www.alliedmarketresearch.com/request-sample/2811

By type, abortion medicine in 2017 occupies more than three-quarters of the world's migraine medicine market. In addition, by oral administration segment, we anticipate a growth rate of up to 3.4% during the forecast period.

North America, along with effective government reforms to raise awareness of migraine and its prevention, was a major revenue contributor to the global market in 2017 due to the surge in demand for better healthcare. However, in the Asia-Pacific region, it is expected to grow at the highest CAGR of 4.4% between 2018 and 2025 due to improved medical infrastructure and better demand for medical facilities.

The report provides an extensive competitive analysis and profiles of the key market players such as Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc. The other players in the value chain (not included in the report) include Novartis International AG, Teva Pharmaceutical Industries Limited, and Sanofi SA.

KEY FINDINGS OF THE STUDY:

• North America occupied a two-fifths share of the global migraine drugs market.

• Oral is anticipated to grow with the highest CAGR throughout the forecast period.

• Europe is anticipated to occupy more than one-fourth market share of the global migraine drugs market by 2025.

• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Browse More Information of Report @ https://www.alliedmarketresearch.com/migraine-drugs-market


About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
[email protected]
Web: www.alliedmarketresearch.com